Research overviews and scientific context for peptides.
Peptide Research
Semax is credited with cognitive enhancement and neuroprotection. The research behind it is real and sits almost entirely inside one national tradition.
Peptide Library Editorial · Oct 7, 2026
Read article →
Peptide Research
MOTS-c is a peptide your own mitochondria encode, which is often offered as a reason it must be safe. Endogenous and safe at any dose are different claims.
Peptide Library Editorial · Oct 5, 2026
Read article →
Peptide Research
Ipamorelin’s reputation rests on what it does not do. The selectivity claim is well founded and narrower than it is usually presented.
Peptide Library Editorial · Oct 4, 2026
Read article →
Peptide Research
BPC-157 is widely described as having no side effects. That claim rests on the absence of anyone systematically looking, which is a very different thing.
Peptide Library Editorial · Oct 2, 2026
Read article →
Peptide Research
Sermorelin is unusual among research peptides in having once been an approved drug — which means an actual adverse-effect record exists rather than only anecdote.
Peptide Library Editorial · Sep 30, 2026
Read article →
Peptide Research
BPC-157 is credited with a remarkably long list of benefits. Tracing each claim back to what actually produced it separates a real preclinical literature from marketing.
Peptide Library Editorial · Sep 29, 2026
Read article →
Peptide Research
Vesugen belongs to a family of very short peptides each assigned to a specific tissue. The framework is unusual, internally consistent, and thinly replicated outside its origin.
Peptide Library Editorial · Sep 27, 2026
Read article →
Peptide Research
Thymalin is an extract rather than a defined compound, from a Soviet-era research programme whose literature is real, extensive, and almost entirely un-replicated in the West.
Peptide Library Editorial · Sep 26, 2026
Read article →
Peptide Research
GHRP-2 sits between ipamorelin and hexarelin on both potency and side effects — which makes it the clearest illustration of the trade-off running through the whole family.
Peptide Library Editorial · Sep 25, 2026
Read article →
Peptide Research
SLU-PP-332 gets sold as a peptide and is not one. It is a small molecule that activates a family of nuclear receptors, and the mouse data behind it are real but early.
Peptide Library Editorial · Sep 19, 2026
Read article →
Peptide Research
Methylene blue is not a peptide and not new — it is a 19th-century dye with a real approved medical use. It also has one interaction serious enough to lead with.
Peptide Library Editorial · Sep 18, 2026
Read article →
Peptide Research
Glutathione is a genuine peptide — three amino acids — and one your body already makes in quantity. That is what makes supplementing it a more complicated question than it looks.
Peptide Library Editorial · Sep 17, 2026
Read article →
Peptide Research
MK-677 does the same job as the injectable growth hormone secretagogues, orally and for far longer. Both of those differences come from it not being a peptide.
Peptide Library Editorial · Sep 13, 2026
Read article →
Peptide Research
Enclomiphene is sold alongside peptides and is not one. It is a selective oestrogen receptor modulator, and its mechanism is the opposite of supplying a hormone.
Peptide Library Editorial · Sep 11, 2026
Read article →
Peptide Research
Retatrutide is the first triple agonist to reach late-stage obesity trials. Understanding it means understanding what a third receptor adds to an already effective pair.
Peptide Library Editorial · Sep 10, 2026
Read article →
Peptide Research
Semaglutide side effects are overwhelmingly gastrointestinal and closely tied to dose changes. A smaller set are not, and those are the ones worth understanding in advance.
Peptide Library Editorial · Sep 2, 2026
Read article →
Peptide Research
Fatigue on tirzepatide is common and mostly downstream of eating far less. That distinction points at what actually fixes it.
Peptide Library Editorial · Aug 17, 2026
Read article →
Peptide Research
Before-and-after photos are the primary evidence offered for sermorelin. They are also the weakest form of evidence available.
Peptide Library Editorial · Aug 13, 2026
Read article →
Peptide Research
Unusually for this market, there is real trial data to compare the photos against. The comparison is the useful part.
Peptide Library Editorial · Aug 12, 2026
Read article →
Peptide Research
Tirzepatide tablets do not exist, and the reason explains most of what is interesting about oral peptide delivery.
Peptide Library Editorial · Aug 9, 2026
Read article →
Peptide Research
Oxytocin is a genuine hormone with an approved medical use and an enormous research literature. It is also the subject of one of the largest gaps between popular reputation and replicated evidence in this field.
Peptide Library Editorial · Aug 8, 2026
Read article →
Peptide Research
Glutathione does something genuinely important. Whether swallowing it changes your levels is a separate question with real trial data.
Peptide Library Editorial · Aug 5, 2026
Read article →
Peptide Research
The efficacy numbers from retatrutide's phase 2 trial get quoted constantly; the tolerability data far less. They came from the same study, and they are not separable.
Peptide Library Editorial · Aug 4, 2026
Read article →
Peptide Research
Unlike every other oral peptide claim in this market, this one is an approved product — and how it works is genuinely clever.
Peptide Library Editorial · Jul 22, 2026
Read article →
Peptide Research
Gonadorelin is one of the few compounds where the administration schedule does not merely change the size of the effect — it reverses its direction entirely.
Peptide Library Editorial · Jul 21, 2026
Read article →
Peptide Research
hCG is a glycoprotein hormone, not a peptide — and it is the one HPG-axis compound that works when the pituitary does not.
Peptide Library Editorial · Jul 19, 2026
Read article →
Peptide Research
Dihexa has one of the more specific mechanisms in this market and one of the thinnest human evidence bases. Both are worth knowing.
Peptide Library Editorial · Jul 6, 2026
Read article →
Peptide Research
PT-141 is one of the few research-market peptides that is also an approved drug — for a specific population most buyers are not in.
Peptide Library Editorial · Jul 4, 2026
Read article →
Peptide Research
LL-37 is not a foreign compound — the body makes it as part of innate immunity. That is what makes it interesting, and also why more of it is not straightforwardly better.
Peptide Library Editorial · Jul 3, 2026
Read article →
Peptide Research
Ipamorelin is a selective growth hormone secretagogue — the selectivity is the whole reason it gets discussed separately from older peptides in its class. Here is what the literature reports and how the vial arithmetic works.
Peptide Library Editorial · Jun 30, 2026
Read article →
Peptide Research
CagriSema is a fixed combination of cagrilintide, an amylin analogue, and semaglutide. It is also the rare peptide combination that was actually tested against its own components — and the trials show what that measurement is worth.
Peptide Library Editorial · Jun 23, 2026
Read article →
Peptide Research
Larazotide got further through clinical development than almost any compound sold as a research peptide — which makes what happened in phase 3 the most informative thing about it.
Peptide Library Editorial · Jun 12, 2026
Read article →
Peptide Research
SS-31 is unusual among research peptides in having a specific molecular target and a real clinical development programme — one that has produced both encouraging and disappointing results.
Peptide Library Editorial · May 26, 2026
Read article →
Peptide Research
Cerebrolysin is not one molecule. It is a preparation of peptide fragments from porcine brain tissue — which makes standardisation, and therefore evaluation, genuinely difficult.
Peptide Library Editorial · May 12, 2026
Read article →
Peptide Research
Adipotide does not modulate appetite or metabolism. It targets the blood supply of fat tissue and triggers cell death — a mechanism categorically different from every other compound here.
Peptide Library Editorial · May 8, 2026
Read article →
Peptide Research
MOTS-c is genuinely unusual: a peptide encoded not in nuclear DNA but in the mitochondrial genome. The research is real and interesting, and almost entirely preclinical.
Peptide Library Editorial · Apr 21, 2026
Read article →
Peptide Research
Follistatin inhibits myostatin, the brake on muscle growth. The striking images associated with that pathway come from lifelong genetic deficiency — not from inhibiting it in an adult.
Peptide Library Editorial · Apr 17, 2026
Read article →
Peptide Research
Survodutide pairs GLP-1 with the glucagon receptor — a different combination from tirzepatide, and one that puts it closer to retatrutide without the third target.
Peptide Library Editorial · Apr 3, 2026
Read article →
Peptide Research
Hexarelin produces the largest growth hormone response of the GHRP family. It also desensitises faster than the others and lacks the selectivity that makes ipamorelin attractive.
Peptide Library Editorial · Mar 17, 2026
Read article →
Peptide Research
AOD-9604 is unusual in having been through a real clinical development programme for obesity — and in that programme not producing the result it needed. That history is the most useful thing to know about it.
Peptide Library Editorial · Mar 10, 2026
Read article →
Peptide Research
Thymosin alpha-1 is approved in dozens of countries and not in the US — a split that makes it one of the more unusual compounds in this category, and one of the better evidenced.
Peptide Library Editorial · Mar 3, 2026
Read article →
Peptide Research
IGF-1 LR3 is engineered to slip past the binding proteins that normally control IGF-1. That single modification extends its half-life enormously — and removes a regulatory system that exists for a reason.
Peptide Library Editorial · Feb 27, 2026
Read article →
Peptide Research
NAD+ gets sold alongside research peptides and discussed in the same breath, but it is not a peptide at all. It is a coenzyme, and almost everything about how it behaves follows from that.
Peptide Library Editorial · Feb 17, 2026
Read article →
Peptide Research
5-Amino-1MQ is a small molecule that blocks a single enzyme. The mouse data behind it are real and specific — and there is no human trial at all.
Peptide Library Editorial · Feb 6, 2026
Read article →
Peptide Research
Kisspeptin is the signal that switches on the reproductive hormone cascade. It has genuine clinical research behind it — mostly as a diagnostic probe rather than a treatment.
Peptide Library Editorial · Jan 20, 2026
Read article →
Peptide Research
Most tirzepatide side effects are gastrointestinal, dose-related, and worst while the dose is changing. A few are not, and those are the ones worth knowing in advance.
Peptide Library Editorial · Jan 16, 2026
Read article →
Peptide Research
Tesofensine is sold alongside peptides but is not one — it is a small-molecule brain drug. Its weight-loss effect was discovered by accident, when it failed at the thing it was designed for.
Peptide Library Editorial · Jan 9, 2026
Read article →
Peptide Research
Melanotan II is not approved anywhere, and unlike most research peptides it has an accumulating case-report literature — which makes it one of the few where documented human harms exist to discuss.
Peptide Library Editorial · Jan 6, 2026
Read article →